Roivant Sciences Ltd. (NASDAQ:ROIV – get rating) has received a “Buy” consensus rating from the six research firms that currently cover the company, MercadoBeat.com reports. Six analysts have given the stock a buy rating. The average 12-month price target among brokers who have updated their hedge on the stock in the past year is $10.83.
Several research companies have recently commented on ROIV. JPMorgan Chase & Co. began coverage of Roivant Sciences in a research report on Thursday, October 27. They set an “overweight” rating and a $7.00 price target on the stock. Citigroup raised its price target on Roivant Sciences from $9.00 to $10.00 and gave the company a “buy” rating in a research report Tuesday, August 16.
Internal activity at Roivant Sciences
In other Roivant Sciences news, Chief Operating Officer Eric Venker sold 16,530 shares of the company in a transaction that took place on Wednesday, August 24. The share was sold at an average price of $3.71, for a total value of $61,326.30. Following the completion of the transaction, the COO now directly owns 1,083,164 shares of the company, valued at $4,018,538.44. The transaction was disclosed in a filing with the SEC, which can be accessed via the SEC website. In other Roivant Sciences news, CEO Matthew Gline sold 19,276 shares of the company in a transaction that occurred on Tuesday, October 25. The share was sold at an average price of $4.40, for a total value of $84,814.40. Following the completion of the transaction, the CEO now directly owns 1,164,009 shares of the company, valued at $5,121,639.60. The transaction was disclosed in a filing with the SEC, which can be accessed via the SEC website. Likewise, the COO Eric Venker sold 16,530 shares of the firm’s capital stock in a transaction that occurred on Wednesday, August 24. The shares were sold at an average price of $3.71, for a total value of $61,326.30. Following the completion of the transaction, the COO now owns 1,083,164 shares of the company, valued at $4,018,538.44. Disclosure of this sale can be found here. In the last quarter, experts sold 115,163 shares of the company valued at $426,918. 13.00% of the shares are owned by insiders.
Institutional entrances and exits
Several hedge funds have recently bought and sold ROIV shares. Two Seas Capital LP increased its stake in Roivant Sciences by 323.8% in the second quarter. Two Seas Capital LP now owns 3,419,836 shares of the company valued at $13,919,000 after purchasing an additional 2,612,929 shares in the last quarter. American International Group Inc. purchased a new position in Roivant Sciences stock during the first quarter worth approximately $8,965,000. Eventide Asset Management LLC increased its stake in Roivant Sciences shares by 141.5% during the first quarter. Eventide Asset Management LLC now owns 1,690,300 shares of the company worth $8,177,000 after purchasing an additional 990,300 shares during the period. Chicago Capital LLC purchased a new position in Roivant Sciences stock during the second quarter worth approximately $3,818,000. Finally, Point72 Asset Management LP purchased a new position in Roivant Sciences stock during the second quarter worth approximately $3,569,000. Currently, 51.44% of the shares are owned by institutional investors.
Roivant Sciences Trading Up 2.2%
NASDAQ:ROIV opened at $5.18 on Friday. Roivant Sciences has a 1-year minimum of $2.52 and a 1-year maximum of $16.76. The firm’s 50-day moving average price is $4.14 and its 200-day moving average price is $4.06. The firm has a current ratio of 6.20, a quick ratio of 6.20, and a debt-to-equity ratio of 0.22. The company has a market cap of $3.64 billion, a P/E ratio of -3.24, and a beta of 1.89.
Root Sciences (NASDAQ:ROIV – get rating) last posted its earnings results on Monday, August 15. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.18). Roivant Sciences had a negative net margin of 2,110.83% and a negative return on equity of 68.61%. The company had revenue of $4.32 million during the quarter, compared to analyst estimates of $6.45 million. On average, stock analysts expect Roivant Sciences to post earnings per share of -1.72 for the current year.
Roivant Sciences company profile
Roivant Sciences Ltd., a biopharmaceutical and health technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapies, including solid tumors, sickle cell disease, hypophosphatasia, oncological malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, eye diseases thyroid, sarcoidosis, and staphylococcus aureus bacteremia.
This instant news alert was powered by MarketBeat’s financial data and narrative science technology to provide readers with the fastest and most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to email@example.com.
Before you consider Roivant Sciences, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five actions that major analysts quietly whisper to their clients to buy now before the broader market realizes it… and Roivant Sciences was not on the list.
While Roivant Sciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.